Hikma appoints new President of Generics business

Hikma Pharmaceuticals Plc

15 April 2024

 

Hikma appoints Dr. Hafrun Fridriksdottir as President of Generics business

London, 15 April 2024 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) announces that Dr. Hafrun Fridriksdottir has been appointed President of its Generics business, effective today. Hafrun will report to Riad Mishlawi, Hikma's Chief Executive Officer, and joins the senior management team as a member of Hikma's Executive Committee.  She will be based in the company's Berkeley Heights, New Jersey offices. Hafrun succeeds Brian Hoffmann, who will leave Hikma effective May 1st.

Hafrun brings more than 25 years of pharmaceutical industry experience to her new role.  During her career, Hafrun has held senior executive and research and development positions at leading global pharmaceutical companies including Alvotech, Teva Pharmaceuticals, Allergan and Actavis, and most recently has served in advisory and board roles for several biotech and mid-sized pharma companies.

"I am pleased to appoint Hafrun to this vital role," said Riad.  "Hafrun's vast experience in leading high performing research and development teams brings new capabilities needed for driving Hikma's Generics business in its next phase of growth. She will be especially helpful in further expanding Hikma's product portfolio and its position as a market-leading domestic US manufacturer and supplier of generic medicines.  On behalf of Hikma's Board of Directors and our executive management team, I want to thank Brian for his many contributions to Hikma during his 15 years with the company."

Hafrun added: "This is a very exciting opportunity for me to lead a highly talented team, who have been growing and developing this business over many years. I am confident that together we will strengthen our R&D pipeline, leverage our strong manufacturing capabilities and establish new business opportunities that will further build our position as one of the top providers of generic medicines in the US."

- ENDS -

Hikma (Investors):                           

Susan Ringdal EVP, Strategic Planning and Global Affairs	[phone]/ [phone]
Guy Featherstone Director, Investor Relations	[phone]/ [phone]
Layan Kalisse Senior Associate, Investor Relations	[phone]/ [phone]

Press:                                                                        

Teneo - Douglas Campbell                                  [phone]/ [phone]

Hikma - Steve Weiss                                           [phone]

About Hikma:

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our over 9,000 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

 

END